Autoimmune neurology
A history of innovation and discovery
The Mayo Clinic Neuroimmunology Laboratory was the first to introduce comprehensive serological evaluations for the diagnosis of paraneoplastic neurologic autoimmune disorders, a group of disorders in which unusual neurologic signs and symptoms are the initial manifestations of cancer.
The laboratory continues to discover and clinically validate novel autoantibody profiles that inform neurological decision-making and guide the search for cancer, leading an evolution in autoimmune neurology diagnosis. Powered by expertise from our research labs, clinical labs, and Autoimmune Neurology Clinic, we have developed panels customized to address specific phenotypes. This approach delivers more clinically actionable results, providing a clear picture of the diagnosis, prognosis, and treatment options.
“Clinicians are used to looking for patterns in their clinical work, and we’re transferring that expertise into a clinical laboratory space. That’s not something that you learn overnight — it’s gained with experience over years.”
Andrew McKeon, M.B., B.Ch., M.D.
News and updates
The latest
This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.
Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.
Find out how our autoimmune/paraneoplastic encephalopathy evaluations can identify multiple antibodies and guide the search for occult cancer.
Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.
Find out how our suite of autoimmune movement disorder testing can help diagnose PDE10A autoimmunity in patients who present with hyperkinetic movement disorders.
Recording coming soon. Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Learn how our autoimmune/paraneoplastic evaluation for encephalopathy uses CSF testing to confirm an autoimmune GFAP meningoencephalomyelitis diagnosis.
Autoimmune encephalitis (AE) is a rare but serious condition, and accurate diagnosis is critical. Misdiagnosis can lead to unnecessary treatments, delayed care, and preventable complications.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about how our movement disorders testing can help diagnose testicular cancer-associated paraneoplastic encephalitis.
Learn more about how our testing protocol is useful in the diagnosis of sorbitol dehydrogenase (SORD) deficiency.
Find out how we use glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder.
Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.